Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Mbiomics GmbH. (3/23/23). "Press Release: Microbiome Therapeutics Biotech Mbiomics Raises EUR 13 Million in First Closing of Series A Round". Munich.

Organisations Organisation Mbiomics GmbH
  Organisation 2 MIG Capital AG
  Group MIG Fonds (Group)
Products Product microbiomic treatment (live biotherapeutic product, LBP)
  Product 2 venture capital
Index term Index term Mbiomics–SEVERAL: investment, 202303 financing round Series A first closing €13m led by MIG Capital
Persons Person Figulla, Laura (Mbiomics 202303 COE + Co-Founder formerly Coramaze Technologies 201401– Managing Director + Co-founder)
  Person 2 Kromayer, Matthias (MIG Funds 201009)

First generation of real microbiome-based therapeutics

mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors.

mbiomics uses its proprietary, tailored high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation. The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision therapies. mbiomics’ core technology also improves patient selection and monitoring for clinical trials, and thus, creates a competitive edge.

“We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies,” said Dr. Laura Figulla, co-founder and CEO of mbiomics. “This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.”

With the announced closing, mbiomics is in a position to spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases. mbiomics will use the proceeds to embark on strategic partnerships, significantly expand their Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.

“The microbiome provides a rich source of new therapeutic possibilities that has yet to be fully explored. We aim to harness the power of the microbiome to treat diseases that have been difficult to address with traditional approaches,” said Dr. Markus Rinecker, co-founder and CMO of mbiomics. Dr. Johannes B. Woehrstein, co-founder and CTO, added: “Our stellar R&D team achieved a technological proof-of-concept for our analytics platform in record time. With this technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.”

Dr. Matthias Kromayer, Managing Partner of MIG Capital, commented: “We are delighted to announce our investment in mbiomics and to back its journey to develop a truly innovative therapeutics platform. The company’s leading-edge approach of combining emerging technologies with the most advanced microbiome research has the potential to significantly improve patient outcomes. We look forward to supporting its ongoing research towards clinical development.”

About mbiomics

mbiomics GmbH, founded in 2020 and based in Munich, Germany, is a privately held biotech company, with a focus on developing the first generation of effective live bacterial therapeutics (LBT). The company is leveraging its tailored microbiome diagnostic platform to overcome current bottlenecks in LBT development – by generating precision profiling data, selecting better informed consortia, improving patient stratification and patient monitoring for clinical trials.

For more information, please visit the company’s website at or contact

About MIG Capital

MIG Capital is one of the leading German VC investors. MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. The company has so far invested over €680 million in about 50 companies. MIG's portfolio companies develop innovations in areas such as biopharmaceuticals, energy and environmental technologies, advanced computing, digitization / IoT, medical technology and digital health. The MIG investment portfolio currently comprises 30 companies.

MIG’s investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, experience and network provide excellent access to companies, institutions and decision-makers in order to support the growth of their portfolio companies.

In recent years, MIG Capital realized more than ten successful sales, including more recently the portfolio companies Siltectra (to Infineon, 2018) and Hemovent (MicroPort, 2021), and led BRAIN (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges.

For further information, please visit:,

MIG media relations

MC Services
Raimund Gabriel, Dr. Johanna Kobler

About High-Tech Gründerfonds

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4.5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies.

Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Contact HTGF

High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Partner Communications & Relations
T.: +49 228 – 82300 – 188

About Bayern Kapital

Bayern Kapital GmbH, based in Landshut (Germany), is the venture/growth capital company of the Free State of Bavaria. It supports innovative high-tech companies in Bavaria through their various growth phases, from seed to later stage, with equity capital from EUR 0.25 to 25 million. Bayern Kapital often closes gaps in the VC area in proven consortium arrangements with private investors (business angels, family offices and corporate ventures).

Bayern Kapital manages specialist investment funds with a volume of around EUR 700 million. Since its formation in 1995 at the initiative of the state government, the wholly-owned subsidiary of LfA Foerderbank Bayern has invested around EUR 400 million of its own equity capital so far in around 300 start-ups and scale-ups from industries such as life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. More than 8,000 long-term jobs in sustainable companies have been created in Bavaria. The active portfolio currently comprises around 80 companies.

Examples of the many ground-breaking success stories that Bayern Kapital has already supported at an early stage include EOS (now the world’s leading technology provider in industrial 3D printing of metals and plastics), Proglove, Fazua, SimScale, Scompler, egym, Parcellab, Cobrainer, Quantum Systems, Casavi, Theva, Riskmethods, Tubulis, Catalym, Immunic, Sirion, tado and many more.

Contact Bayern Kapital

IWK Communication Partner
Florian Bergmann
Ohmstraße 1, 80802 München
+49 89 200030-39

Record changed: 2024-01-20


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top